The prospect of targeting T cell immunoglobulin and mucin-domain containing-3 in renal cell carcinoma immunotherapy
Abstract
Despite the advances in the diagnosis and treatment of renal cell carcinoma
(RCC), it remains one of the most deadly urological cancers. At present, using immune
checkpoint inhibition and their combination with antiangiogenic therapy
is the standard of care in patients with advanced RCC. Unfortunately, a considerable
part of tumour-bearing
hosts does not benefit from this type of treatment.
However, our knowledge about the detailed role of mucin-domain
containing-3
(TIM-3)
in the RCC cells is little, and further studies are required in this field, but
its significant expression in the RCC microenvironment makes this receptor a
promising target for designing new monoclonal antibodies alone or in combination
with other checkpoint inhibitors for RCC immunotherapy.
ارسال نظر